Second-generation antipsychotics (SGAs) are widely used in treating schizophrenia, bipolar disorder, and other psychiatric conditions, but their use comes with essential metabolic and physiological monitoring requirements. These medications—like risperidone, olanzapine, quetiapine, aripiprazole, and others—can cause significant weight gain, dyslipidemia, insulin resistance, and even extrapyramidal symptoms. Regular monitoring is crucial to detect and manage these risks early.
This section serves as a comprehensive reference for psychiatric NPs, outlining baseline and ongoing lab work: fasting glucose, lipid panels, BMI, waist circumference, and blood pressure, as well as prolactin levels and movement disorder assessments when indicated. With this panel, you can ensure safe, evidence-based use of SGAs and protect your patients from the long-term consequences of unchecked side effects.